Sunday, 17 June 2012

Open Innovation in early Pharma: #1

Networked Pharma – Finance (NWkRx F4)

I recently spoke with Jordi Rafols of Innoget, regarding open innovation and the Innoget platform. We began by Jordi  distinguished OI from crowdsourcing as follows:

  • Operates on a shared responses basis, with no confidentiality nor contractual agreements. Individuals post responses to a request and all can see all responses.
  • Good for ideas generation, consumer insights, marketing innovation.
Open innovation:
  • Operates on confidential response basis. Does not pool responses.
Innoget’s website acts as a portal for open innovation, where technology requests or technology offerings can be posted, anonymously if desired, and responses are then made via the website.

Jordi will elaborate further on this approach and its application to pharma discovery during Networked Pharma’s Networked Pharma Funds & Fundability workshop at Holiday Inn, Regents Park, London, on 28th June.

The workshop will examine who is funding, what they are funding and what makes a fundable investment, as well as the rise of open innovation & crowdsourcing. Jordi will be joined by speakers from biotech, VC, CVC, Pharma, CROs, BBSRC, the Wellcome Trust, TSB/KTN and others. For more information and to register see

BioSpring Ltd is a member of Networked Pharma Partnership, a not for profit organisation dedicated to assisting development of a new paradigm for drug discover & development

Networked Pharma PartnershipBuilding Innovative Networks in Drug Discovery & Development

A series of workshops are being run during 2012, leading to an international congress in early 2013, which will bring together all stake-holders (Corporate Pharmas, SMEs, CROs, Universities, VCs, CVCs, Research Councils, Charities, Regulators & Government bodies etc.) to formulate the new business model(s) for the future success of the industry.

Follow us:
Twitter @NWkPharma,      #NWkRx

No comments:

Post a Comment